[Summary] Application of single-cell analysis technology
Singleron Biotechnologies is dedicated to applying breakthrough single-cell technologies to the fields of scientific research, clinical testing, health management, and drug development. Singleron Biotechnologies is dedicated to applying breakthrough single-cell technologies to the fields of scientific research, clinical testing, health management, and drug development. The company was registered and established in January 2018. In May 2018, it secured a tens-of-millions-of-yuan angel round led by Oriza Seed. In June 2019, it obtained a nearly-100-million-yuan Pre-A round led by Sherpa Healthcare Partners. In September, November, and December 2020, it successively completed Series A, A1, and A2 rounds totaling approximately US$70 million. In November 2021, it secured a nearly-US$100-million Series B round led by CBC Group. To date, Singleron has raised nearly US$200 million in total. It has laboratories and offices in Nanjing, Suzhou, Germany, the United States, and Singapore, and has served more than 4,000 research institutions, hospitals, and pharmaceutical companies in nearly 20 countries worldwide. After its establishment, the company quickly attracted a group of high-level entrepreneurial talents, and multiple individuals were selected into talent introduction programs such as "Entrepreneurship Jiangbei," "Entrepreneurship Nanjing," "Suzhou Industrial Park Major*," "Gusu*," and "Jiangsu Province Dual-Innovation Talent." Core team members have worked for many years in genetic testing, microfluidic system R&D, single-cell amplification and library construction reagent product development, bioinformatics analysis and database construction, instrument design and development, and clinical testing product development, possessing mature and profound experience in technological innovation and product development as well as rich and successful commercialization outcomes. The company signed a licensing agreement with Yale University for microfluidic single-cell processing patents, and using this patent together with its proprietary single-cell amplification technology, developed the innovative GEXSCOPE® single-cell technology platform based on microfluidic chips, breaking through the bottlenecks of conventional single-cell sequencing technology in terms of turnaround time, throughput, and cost, and removing obstacles for the application of single-cell analysis technology in clinical testing. The company is committed to independently developing innovative technologies and has obtained 94 patents in areas such as instrument and microfluidic system design, single-cell amplification and library construction methods and workflows, and data analysis algorithms, as well as 87 software copyrights. In January 2019, it launched single-cell transcriptome sequencing products, including a complete solution of microfluidic chips, reagents, and bioinformatics analysis software. In 2020, it launched Singleron Matrix®, an automated single-cell sequencing preprocessing instrument. Currently, the company has established strategic cooperation with multiple universities and hospitals at home and abroad to jointly promote the clinical application of single-cell technology. At the same time, in the fierce competition of the "China Innovation & Entrepreneurship Competition" hosted by the Ministry of Science and Technology, the company stood out from more than 10,000 participating enterprises and won the Excellence Award in the National Biomedicine Finals for two consecutive years in 2018 and 2019, fully representing industry experts' and the market's recognition of the company's team, core technologies, and business model. As a breakthrough new technology, single-cell analysis technology is expected to gradually replace traditional bulk-sample next-generation sequencing. Currently, the global potential scientific research market has reached more than US$13 billion, and the segmented market for single-cell sequencing technology is growing year by year at an average annual rate of more than 20%. The application prospects of single-cell analysis technology in clinical and drug development are even broader; it can replace or supplement existing technologies for molecular, cellular, and tissue pathology testing, and can also be used for emerging cell therapies. Singleron upholds the innovative philosophy of "investigating things to attain knowledge, discerning the微小 to understand the origin" and is committed to developing simple and reliable massive single-cell omics technologies, making them a new-generation means of cellular and molecular pathology and blood testing, and enabling single-cell omics to serve fields such as precision medicine and health management with high accuracy, high sensitivity, and high resolution.
What does Singleron (Nanjing) Biotechnology Co., Ltd. require? Who is Singleron Biotechnologies hiring? Singleron Biotechnologies recruitment: Sales占比最多占91.2%,其次是Scientific Research占56.1%. What education can get in at Singleron Biotechnologies? 本科占比最多占61.4%,其次是硕士占31.6%. High education required at Singleron Biotechnologies? 硕士占31.6%. Work experience required at Singleron Biotechnologies? 1-3年占比最多占59.6%,其次是不限占35.1%. Where are the job locations at Singleron Biotechnologies? 南京占比最多占17.5%,其次是北京占10.5%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows